On Tuesday at 2:04 PM (Bangkok time), the share price of MEDEZE Group Public Company Limited (SET: MEDEZE) rose by 4.14% or THB 0.30 to THB 7.55, with a trading value of THB 13.53 million.
The surge in stock price was attributed to the company’s robust financial performance for the first quarter of 2025, ended 31 March 2025. The stem cell and immune cell services provider reported a substantial increase in both top-line revenue and net profit compared to the same period last year.
For 1Q25, MEDEZE posted total revenue of Baht 228.74 million, an impressive increase of 20% from Baht 190.00 million recorded in 1Q24. Revenue from sales and services, the Group’s core operation, grew by 12% year-on-year to Baht 205.08 million.
Profitability also saw significant gains. Net profit for the quarter reached Baht 74.63 million, marking a 27% increase compared to Baht 58.91 million reported in 1Q24. The net profit margin improved year-on-year by 5% to 33%. Operating profit (EBITDA) demonstrated strong growth as well, increasing by 26% year-on-year to Baht 101.82 million, with the EBITDA margin rising 12% to 50%. The gross profit margin was maintained at 78%, consistent with the previous year.
Key business developments during the quarter included the establishment of MEDEZE Hair Renaissance, a new subsidiary focused on hair follicle cell services, which contributed revenue in its first quarter of operation. The Group also signed an MOU to expand its cell storage base through dealers and explored opportunities in the Philippines market.
Looking ahead, MEDEZE has set a 2025 revenue target exceeding Baht 1,000 million, projecting continued strong growth.
Furthermore, MEDEZE has announced that its wholly owned subsidiary, Medeze Treasury Pte. Ltd. (MT), is making a significant investment through a voluntary conditional cash partial offer. The target of this offer is Cordlife Group Limited, a company incorporated in a foreign country and listed on the Singapore Exchange (SGX).
The offer, approved by the Medeze Group Board of Directors on 12 May 2025, aims to acquire 25,630,774 shares in Cordlife Group Limited. These shares represent 10 percent of the total shares in Cordlife Group Limited (excluding treasury stock).
MT is proposing to pay Singapore Dollar 0.25 in cash for each Offer Share. The total value of this partial offer is approximately Baht 165 million. Payment will be made in cash directly to Cordlife Group Limited’s shareholders who choose to accept the offer.
The transaction is expected to take place within July 2025. The investment aligns with MT’s objective to invest through financial instruments, including acquiring common shares in foreign stock exchanges, to seek the best returns within the framework of Medeze Group’s Investment Policy.
Funding for this transaction will come from an increase in the registered capital of MT. As MT’s shareholder, Medeze Group has approved the transfer of funds to increase MT’s capital, also in line with a resolution from the 2025 Annual General Meeting of Shareholders.
